arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Bolt Biotherapeutics, Inc.

BOLT

$4.06 ▲ +0.16 (+4.10%) at close

26 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Bolt Biotherapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.8M

Dividend Yield —

Revenue Growth -97.9%

Op. Margin None

ROIC -30.3% ↘

FCF / Share $-4.77

Trailing P/E —

Price / Book 0.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$26.00K

↓ -97.9% —

Net Income Profit after all expenses

$-7.24M

↑ +34.4% —

Operating Margin Operating profit as % of sales

-283.4%

↑ +20.2% 0th

FCF / Share Free cash flow per share

$-4.77

↓ -27291.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	-97.9% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1323%)	—	90.1% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1026%)	41.5% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+419%)	-76.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1060%)	N/M	-54.9% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-786%)	-11.0% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-238%)	188.8% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2260%)	48.1% Excellent → Excellent Stable Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+501%)	19.7% Good ↓ Good Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+146%)	2.9% Caution ↓ Caution Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-64%)	124.6% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1458%)	177.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2122%)	180.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+2161%)	—	—	—	—	N/M	—	—	—	—	—	—
EPS Growth YoY (%)	-29624.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	53.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	53.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-15828.6% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-3.6% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-35346.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-36783.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-16.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	37.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	11.3% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	25.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	21.3% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	—	27.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	7.9% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	34.4% Excellent ↓ Excellent Declining Year-over-year change in net income	58.4% Excellent ↑ Excellent Improving Year-over-year change in net income	52.9% Excellent ↑ Excellent Improving Year-over-year change in net income	59.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-2.1% Weak ↓ Weak Declining Year-over-year change in net income	11.0% Fair ↑ Fair Improving Year-over-year change in net income	6.6% Fair ↓ Fair Declining Year-over-year change in net income	-17.4% Weak ↓ Weak Declining Year-over-year change in net income	36.3% Excellent ↑ Excellent Improving Year-over-year change in net income	10.5% Fair ↓ Fair Declining Year-over-year change in net income	25.3% Excellent → Excellent Stable Year-over-year change in net income	20.3% Good → Good Stable Year-over-year change in net income	28.3% Excellent ↑ Excellent Improving Year-over-year change in net income	26.4% Excellent ↑ Excellent Improving Year-over-year change in net income	7.0% Fair ↑ Fair Improving Year-over-year change in net income	3.9% Caution ↑ Caution Improving Year-over-year change in net income	3.2% Caution ↑ Caution Improving Year-over-year change in net income	12.5% Fair ↑ Fair Improving Year-over-year change in net income	-133.9% Weak ↑ Weak Improving Year-over-year change in net income	-113.3% Weak Weak Year-over-year change in net income	-183.3% Weak Weak Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%)	-27291.9% Weak Weak Year-over-year change in free cash flow	—	30.8% Excellent Excellent Year-over-year change in free cash flow	—	20.8% Good Good Year-over-year change in free cash flow	—	-32693.9% Weak Weak Year-over-year change in free cash flow	—	29.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	—	-17.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	29.5% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	6.7% Fair Fair Year-over-year change in free cash flow	—	28.6% Excellent Excellent Year-over-year change in free cash flow	—	13.8% Fair Fair Year-over-year change in free cash flow	—	92.3% Excellent Excellent Year-over-year change in free cash flow	—	85.1% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—
Revenue CAGR 3Y (%)	-75.8% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	21.0% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	0.9% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	9.0% Fair ↓ Fair Declining Compound annual revenue growth over 3 years	14.5% Good Good Compound annual revenue growth over 3 years	—	14.9% Good Good Compound annual revenue growth over 3 years	—	—	—	—	177.6% Excellent Excellent Compound annual revenue growth over 3 years	123.3% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—	—	—	—	—	—	—	—
Revenue CAGR 5Y (%)	—	—	—	93.2% Excellent Excellent Compound annual revenue growth over 5 years	49.4% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	—	-283.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1989%)	-355.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2468%)	—	—	—	—	—	-324.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2261%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit Margin (%) (%)	—	-265.2% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2310%)	-329.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2845%)	-474.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4055%)	—	—	—	—	-205.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1808%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF Margin (%) (%)	—	-286.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-448.7% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	-317.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	1.11x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	1.08x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	1.36x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.12x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.21x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	—	1.55x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.04x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.38x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.65x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	—	0.68x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.44x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.37x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.19x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.16x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-30.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-21.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-19.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-18.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-20.4% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-23.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-18.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-20.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.2% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-9.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	12.7% Good → Good Stable Return earned on debt + equity capital invested Optimal: > 10%	13.1% Good → Good Stable Return earned on debt + equity capital invested Optimal: > 10%	13.5% Good Good Return earned on debt + equity capital invested Optimal: > 10%	12.7% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-15.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.5% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-11.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-12.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-14.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-17.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	—	-18.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-12.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-8.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-9.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-8.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-8.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	—	-6.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-5.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-36.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-36.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-344%)	-25.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-267%)	-22.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-248%)	-22.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-247%)	-23.6% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-257%)	-27.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-286%)	-21.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-240%)	-24.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-265%)	-10.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-169%)	-15.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-206%)	-12.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-185%)	-12.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-185%)	-10.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-172%)	-11.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-178%)	-11.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-177%)	-10.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-173%)	-10.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-169%)	-10.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-172%)	-8.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-157%)	-8.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-153%)	-8.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-154%)	29.6% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+97%)	13.4% Fair ↓ Fair Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-11%)	17.0% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+13%)	15.9% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+6%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-11.61M	$-11.70M	$-17.75M	$-9.60M	$-8.39M	$-7.21M	$-9.37M	$-6.20M	$-4.26M	$-10.81M	$-9.16M	$-13.45M	$-14.84M	$-9.24M	$-10.62M	$-22.62M	$-44.02M	$-27.38M	$-23.65M	$-58.30M	$-95.48M	$-5.54M	$-17.79M	$-45.31M	$-11.61M	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.02	—	$1.13	$0.94	$0.00	—	$0.60	$0.00	$0.01	—	$0.00	$0.00	$0.00	—	$0.00	$0.00	$0.00	—	$0.00	$0.00	—	—	$0.00	$0.00	$0.00	—
Basic EPS, GAAP (USD)	$-4.31	$-3.91	$-3.72	$-4.46	$-0.01	$-8.33	$-7.93	$-0.03	$-0.01	$-0.02	$-0.02	$-0.02	$-0.02	$-0.03	$-0.03	$-0.03	—	$-0.04	$-0.03	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-4.77	—	$-5.07	$-5.00	$-0.02	—	$-7.32	—	$-0.02	—	$-0.02	$-0.02	$-0.03	—	$-0.02	$-0.03	$-0.03	—	$-0.03	—	$-0.04	—	$-0.34	$-0.34	$-0.26	—
Book Value per Share (USD)	$10.32	$13.80	$16.72	$20.24	$0.06	$29.84	$37.66	$0.11	$0.14	$0.15	$0.17	$0.19	$0.21	$0.23	$0.25	$0.28	$0.30	$0.33	$0.37	$0.40	$0.42	$-2.46	$-1.88	$-1.68	$-1.40	—
Tangible Book Value per Share (USD)	$10.32	$13.80	$16.72	$20.24	$0.06	$29.84	$37.66	$0.11	$0.14	$0.15	$0.17	$0.19	$0.21	$0.23	$0.25	$0.28	$0.30	$0.33	$0.37	$0.40	$0.42	$-2.46	$-1.88	$-1.68	$-1.40	—
Basic Weighted Avg Shares (shares)	1.68M	—	1.92M	1.92M	766.79M	—	1.91M	762.57M	761.37M	—	757.37M	755.01M	753.68M	—	749.09M	745.87M	748.67M	—	744.14M	732.35M	430.14M	—	39.66M	38.75M	38.67M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$18.41M	$21.82M	$25.64M	$26.03M	$28.95M	$34.96M	—	$58.73M	$78.33M	$85.25M	—	—	$115.36M	$149.63M	—	—	$176.78M	$167.83M	—	$228.90M	$259.20M	$14.10M	—	—	—	—
Total Equity (USD)	$19.82M	$26.50M	$32.10M	$38.84M	$46.81M	$57.20M	$72.03M	$85.86M	$104.16M	$112.74M	$128.26M	$142.13M	$157.69M	$171.51M	$188.45M	$207.97M	$228.39M	$250.12M	$274.91M	$295.90M	$303.25M	$-104.95M	$-74.59M	$-65.04M	$-54.23M	$-45.85M

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$26.00K	$2.50M	$2.17M	$1.80M	$1.22M	$0.00	$1.14M	$1.27M	$5.27M	$2.09M	$2.53M	$1.43M	$1.83M	$1.41M	$2.11M	$1.39M	$813.00K	$508.00K	$752.00K	$0.00	—	$0.00	$0.00	$67.00K	$164.00K	—
Depreciation Expense (USD)	$203.00K	$255.00K	$290.00K	$347.00K	$399.00K	$426.00K	$440.00K	$400.00K	$458.00K	$467.00K	$462.00K	$458.00K	$467.00K	$462.00K	$439.00K	$408.00K	$357.00K	$361.00K	$304.00K	$200.00K	$272.00K	$221.00K	$179.00K	$110.00K	$101.00K	—
Net Income, GAAP (USD)	$-7.24M	$-6.63M	$-7.14M	$-8.56M	$-11.04M	$-15.94M	$-15.18M	$-21.20M	$-10.81M	$-17.90M	$-16.26M	$-18.06M	$-16.98M	$-20.00M	$-21.76M	$-22.66M	$-23.68M	$-27.16M	$-23.39M	$-23.59M	$-24.45M	$-31.04M	$-10.00M	$-11.06M	$-8.63M	—
Operating Cash Flow (USD)	$-8.02M	$-7.16M	$-9.73M	$-9.60M	$-13.37M	$-14.43M	$-13.97M	—	$-16.75M	$-14.27M	$-16.75M	$-15.11M	$-23.40M	$-17.95M	$-13.45M	$-20.79M	$-24.31M	$-17.79M	$-18.73M	—	$-16.56M	$-12.89M	$-12.52M	$-12.27M	$-9.64M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Bolt Biotherapeutics, Inc.

Analytical Summary

26-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BOLT with peers